Can AFP be elevated without cancer?

Yes. Modest AFP elevations occur in chronic hepatitis, cirrhosis, acute liver injury, and pregnancy. Persistent or rising AFP in cirrhosis prompts imaging to exclude superimposed hepatocellular carcinoma.

How is AFP used in hepatocellular carcinoma surveillance?

In patients with cirrhosis or chronic hepatitis B, AFP is measured every six months alongside liver ultrasound to detect early hepatocellular carcinoma. A rising AFP or level above 20–200 ng/mL (depending on guideline) triggers further imaging.

Is AFP elevated in all hepatocellular carcinomas?

No. Approximately 40 per cent of hepatocellular carcinomas, particularly small tumours, do not produce elevated AFP, which is why imaging remains the cornerstone of surveillance and diagnosis.

How does AFP relate to germ-cell tumour staging?

In non-seminomatous germ-cell tumours, AFP is measured with beta-hCG and LDH; the degree of elevation contributes to International Germ Cell Cancer Collaborative Group (IGCCCG) risk stratification and guides treatment intensity.

Does pregnancy affect AFP results?

Yes. AFP is physiologically elevated during pregnancy, peaking in the second trimester. Pregnancy must be excluded before attributing an elevation to malignancy.

Should AFP be measured in the same laboratory over time?

Serial monitoring is best performed in the same laboratory using the same assay platform, as reference ranges and absolute values differ between methods. The routing laboratory is noted for this reason.

How quickly are AFP results available?

Results are typically available within 1–3 business days from specimen receipt at the processing laboratory. Urgent requests for treatment monitoring may be expedited.

BML-CAN-004cancer biomarkersUSA

AFP (Tumor Marker)

Q: What does a falling AFP after treatment mean?

A predictable fall in AFP after surgery or chemotherapy, consistent with its five-to-seven-day half-life, indicates effective tumour clearance. Lack of fall or a plateau suggests incomplete resection or chemoresistance.

The AFP tumour marker test measures serum alpha-fetoprotein, an oncofetal glycoprotein re-expressed in hepatocellular carcinoma and non-seminomatous germ-cell tumours. It is used for surveillance in cirrhosis, evaluation of liver masses, staging and monitoring of germ-cell neoplasms, and tracking treatment response; modest elevations occur in chronic liver disease and pregnancy.

Biomarkers

Blood (serum)

Sample

1–3 business days

Turnaround

Fasting

What is the AFP test?

The AFP tumour marker test measures serum alpha-fetoprotein, an oncofetal protein whose re-expression in adults signals dedifferentiation in hepatocellular carcinoma and certain germ-cell neoplasms. Practitioners order AFP to screen high-risk patients with cirrhosis for hepatocellular carcinoma—typically in combination with liver ultrasound—to evaluate a liver mass found on imaging, and to stage, risk-stratify, and monitor treatment response in non-seminomatous germ-cell tumours of the testis or ovary. Because AFP is not wholly specific to malignancy—chronic hepatitis and cirrhosis can produce modest elevations, and pregnancy is a physiological cause—interpretation hinges on magnitude, trend, and clinical context rather than a single threshold. The half-life of five to seven days means that a fall in AFP after surgery or chemotherapy reflects effective tumour clearance, while a plateau or rise signals residual or recurrent disease. AFP is part of a broader diagnostic picture: in germ-cell tumours it is read alongside beta-hCG and LDH, and in hepatocellular carcinoma alongside imaging and liver function.

What does the AFP test measure?

AFP(Alpha-Fetoprotein)

Range: Typically <10 ng/mL in non-pregnant adults; paediatric and neonatal levels are substantially higher and decline over the first year of life.Optimal: In the context of cancer surveillance or follow-up, practitioners aim for AFP to remain below the laboratory's upper reference limit (commonly <10 ng/mL) and to fall appropriately after treatment; persistently elevated or rising AFP prompts imaging or reconsideration of therapy.ng/mL / µg/L / IU/mL

Alpha-fetoprotein is an oncofetal glycoprotein produced by the foetal yolk sac, liver, and gastrointestinal tract during gestation. Serum concentrations peak in foetal circulation around 12–14 weeks and fall rapidly after birth, reaching adult levels by one year. In adults, AFP expression is normally repressed; re-expression signals dedifferentiation in hepatocellular carcinoma, non-seminomatous germ-cell tumours, and occasionally gastric or pancreaticobiliary malignancies. The half-life in serum is five to seven days, making it useful for monitoring treatment response and detecting recurrence.

AFP is a tumour marker for hepatocellular carcinoma and non-seminomatous germ-cell tumours (yolk-sac tumour, embryonal carcinoma, mixed germ-cell tumours). Elevated concentrations are seen in active hepatocellular carcinoma, where AFP is used alongside imaging for surveillance in cirrhosis and to monitor therapy response. In testicular and ovarian germ-cell tumours, AFP is measured with beta-hCG and LDH as part of staging and risk stratification. Modest elevations occur in non-malignant liver disease (acute and chronic hepatitis, cirrhosis) and during pregnancy, so clinical context and trends are essential to interpretation.

Why is the AFP test ordered?

Surveillance for hepatocellular carcinoma in patients with cirrhosis (any aetiology) or chronic hepatitis B, typically every six months with liver ultrasound
Evaluation of a liver mass or nodule detected on imaging, to help distinguish hepatocellular carcinoma from benign lesions or other malignancies
Staging and risk stratification of newly diagnosed non-seminomatous germ-cell tumours of the testis or ovary, measured with beta-hCG and LDH
Monitoring treatment response and detecting recurrence after surgery or chemotherapy for hepatocellular carcinoma or germ-cell tumours, with serial measurements
Investigation of an incidental or unexplained AFP elevation found on a routine panel, particularly in the presence of liver disease or a palpable testicular mass
Assessment of rare AFP-secreting gastric, pancreatic, or biliary malignancies when suggested by imaging and clinical presentation
Paediatric oncology evaluation of suspected hepatoblastoma or germ-cell tumour, where age-adjusted reference ranges are essential
Prenatal screening for neural-tube defects and chromosomal abnormalities (measured in maternal serum or amniotic fluid; separate from the oncology indication)

Sample collection and turnaround

Sample type

Blood (serum)

Fasting required

Collection method

Venipuncture at patient service centre

Turnaround

1–3 business days

Collection notes

Phlebotomy at the processing laboratory's draw site (LabCorp or Access Medical Laboratories, depending on routing); no special preparation. Separate serum from cells promptly. For serial monitoring, the same laboratory and assay platform are preferred to ensure comparability.

Specimen requirements

Minimum 0.5 mL serum (gel separator acceptable). AFP is stable refrigerated for up to one week and frozen for longer storage. Avoid grossly haemolysed specimens, which may interfere with immunoassay.

What can affect AFP results?

elevatesPregnancy

AFP is physiologically elevated during pregnancy, peaking in the second trimester; levels return to baseline after delivery, so pregnancy must be excluded before attributing elevation to malignancy.

elevatesAcute and chronic liver disease

Active hepatitis (viral, autoimmune, drug-induced) and cirrhosis can produce modest AFP elevations (typically <200 ng/mL) through hepatocyte regeneration; a stable mildly elevated AFP in chronic liver disease requires ongoing surveillance to detect superimposed hepatocellular carcinoma.

elevatesAtaxia-telangiectasia and hereditary tyrosinaemia

These rare genetic disorders can produce persistent AFP elevation; clinical features and genetic testing distinguish them from malignancy.

reducesRecent surgery or chemotherapy

Successful tumour resection or chemotherapy leads to a predictable fall in AFP (half-life five to seven days); lack of fall suggests incomplete resection or chemoresistance.

variableHaemolysis or sample degradation

Grossly haemolysed specimens may affect immunoassay performance; samples should be processed promptly and stored appropriately.

variableHeterophile antibodies and assay interference

Rare immunoassay interference from heterophile or human anti-animal antibodies can produce falsely elevated results; discordant clinical picture warrants re-testing with a different platform or method.

What do AFP results mean?

Elevated

Marked elevation (>400–500 ng/mL) in the appropriate clinical context strongly suggests hepatocellular carcinoma or non-seminomatous germ-cell tumour. Moderate elevation (10–400 ng/mL) occurs in active liver disease, cirrhosis, and occasionally gastrointestinal malignancies; imaging and clinical correlation are essential. In germ-cell tumours, the degree of elevation contributes to IGCCCG risk stratification. Serial rising AFP after treatment signals recurrence or progression.

Normal

Normal AFP does not exclude hepatocellular carcinoma—approximately 40% of small hepatocellular carcinomas are AFP-negative—so surveillance relies on imaging as well. In pure seminoma or teratoma, AFP is not elevated. A normal baseline AFP in a germ-cell tumour reduces risk stratification but does not obviate other markers.

Reduced

Low or undetectable AFP is expected in healthy adults and following successful treatment of an AFP-secreting tumour. A falling AFP post-therapy, consistent with the five-to-seven-day half-life, indicates effective tumour clearance.

Note: AFP must be interpreted with imaging, other tumour markers (beta-hCG, LDH), and liver function. Magnitude, trend, and half-life kinetics matter more than a single value. Pregnancy, active hepatitis, and cirrhosis produce non-malignant elevations. Reference ranges differ between laboratories and assay platforms, so serial monitoring should use the same laboratory where feasible.

Frequently asked questions

AFP is elevated in hepatocellular carcinoma and non-seminomatous germ-cell tumours (yolk-sac tumour, embryonal carcinoma, mixed germ-cell tumours). It is occasionally raised in gastric, pancreatic, or biliary malignancies but is not routinely used for those.

How to access the AFP test

The AFP reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.

Create Free Account

About this page

Published: October 7, 2026

Last reviewed: October 7, 2026

References:

Marrero JA, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. (2018)
Gilligan T, et al. Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. (2019)
International Germ Cell Cancer Collaborative Group (IGCCCG) classification and risk stratification of metastatic germ cell tumours. (1997)
European Association for the Study of the Liver (EASL) clinical practice guidelines: management of hepatocellular carcinoma. (2018)
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology (AASLD practice guideline). (2011)

This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.